Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (81-90 of 263) with videos related to

Pageof 27
Sort By:
Cancer|July 9, 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemiaCarlos E Bueso-Ramos, Jorge Cortes, Moshe Talpaz, et al.
Molecular Cancer Therapeutics|May 14, 2015
CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and MetastasisDaniela Burgos-Ojeda, Rong Wu, Karen McLean, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapyDon L Gibbons, Sabrina Pricl, Paola Posocco, et al.
Cancer|October 30, 2003
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseJorge Medina, Hagop Kantarjian, Moshe Talpaz, et al.
Oncogene|October 12, 2018
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growthKaren McLean, Lijun Tan, Danielle E Bolland, et al.
Leukemia & Lymphoma|July 16, 2005
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
Tomography (Ann Arbor, Mich.)|August 27, 2025
Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of MyelofibrosisLauren Brenner, Tanner H Robison, Timothy D Johnson, et al.
JCO Precision Oncology|September 11, 2020
Oncologists' Use of Genomic Sequencing Data to Inform Clinical ManagementMichele C Gornick, Erin Cobain, Lan Q Le, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2018
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable CytogeneticsVincent T Ma, Philip S Boonstra, Kamal Menghrajani, et al.
Leukemia|May 22, 2026
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemiaAndreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, et al.
Pageof 27

Showing results (81-90 of 263) with videos related to

Sort By:
Pageof 27
Cancer|July 9, 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemiaCarlos E Bueso-Ramos, Jorge Cortes, Moshe Talpaz, et al.
Molecular Cancer Therapeutics|May 14, 2015
CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and MetastasisDaniela Burgos-Ojeda, Rong Wu, Karen McLean, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapyDon L Gibbons, Sabrina Pricl, Paola Posocco, et al.
Cancer|October 30, 2003
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseJorge Medina, Hagop Kantarjian, Moshe Talpaz, et al.
Oncogene|October 12, 2018
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growthKaren McLean, Lijun Tan, Danielle E Bolland, et al.
Leukemia & Lymphoma|July 16, 2005
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
Tomography (Ann Arbor, Mich.)|August 27, 2025
Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of MyelofibrosisLauren Brenner, Tanner H Robison, Timothy D Johnson, et al.
JCO Precision Oncology|September 11, 2020
Oncologists' Use of Genomic Sequencing Data to Inform Clinical ManagementMichele C Gornick, Erin Cobain, Lan Q Le, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2018
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable CytogeneticsVincent T Ma, Philip S Boonstra, Kamal Menghrajani, et al.
Leukemia|May 22, 2026
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemiaAndreas Hochhaus, Moshe Talpaz, Giuseppe Saglio, et al.
Pageof 27